Login / Signup

A long-acting pegylated recombinant human growth hormone (Jintrolong® ) in healthy adult subjects: Two single-dose trials evaluating safety, tolerability and pharmacokinetics.

Yanping GuanF HeJ WuL ZhaoX WangL HuangG ZengB RenJ ChenX LiaoZ MaX ChenG ZhongM HuangX Zhao
Published in: Journal of clinical pharmacy and therapeutics (2018)
Single-dose Jintrolong® injection was well tolerated in healthy adult subjects, and the maximum tolerable dose was no lower than 0.8 mg/kg. Jintrolong® was long-acting with the potential for weekly administration.
Keyphrases
  • recombinant human
  • growth hormone
  • open label
  • childhood cancer
  • clinical trial
  • randomized controlled trial
  • young adults
  • ultrasound guided